Premium
Adjuvant methotrexate‐5‐fluorouracil for extracapsular squamous cell carcinoma in cervical metastasis
Author(s) -
Johnson Jonas T.,
Myers Eugene N.,
Sigler Barbara A.,
Wagner Robin L.,
Mayernik David G.,
Nolan Teresa A.
Publication year - 1990
Publication title -
the laryngoscope
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.181
H-Index - 148
eISSN - 1531-4995
pISSN - 0023-852X
DOI - 10.1288/00005537-199006000-00007
Subject(s) - medicine , methotrexate , chemotherapy , adjuvant , fluorouracil , surgery , oncology , radiation therapy , stage (stratigraphy) , metastasis , adjuvant therapy , randomized controlled trial , carcinoma , cancer , paleontology , biology
A trial of surgery, irradiation, and adjuvant chemotherapy was offered to patients with extracapsular spread of squamous cell carcinoma in cervical metastases. Following surgery and irradiation, methotrexate, 5‐fluorouracil, and Ieucovorin were administered 18 times over 6 months. Fifty patients undertook chemotherapy, while 47 patients declined further therapy. Comparison of the two groups according to stage, site, and Karnofsky performance status demonstrated no significant differences. The number of nodes encountered and the number and percentage of nodes with extracapsular spread were similar in the two groups. The minimum 5‐year adjusted survival for patients undergoing adjuvant chemotherapy is 54% (20 of 37 patients), while survival of patients who failed to undertake adjuvant chemotherapy was 17% (5 of 30 patients). These data suggest the efficacy of methotrexate‐5‐fluorouracil adjuvant chemotherapy and support the need for a prospective randomized clinical trial.